7412
CH2Cl2, and gave Merrifield-derived resin 10®=M, which was dried under nitrogen. Merrifield-
derived resin 10®=M was treated with phenyl isocyanate (0.32 g, 2.72 mmol) in THF (10 mL) at
60°C overnight to sequentially effect urea formation (giving 11®=M) and cyclo-elimination to
produce hydantoin 12. The resin was washed with THF and the combined organic solvent was
evaporated under reduced pressure. The resulting residue was purified by short-pass column
chromatography (20% ethyl acetate in hexane) to give 12 (0.191 g, 0.63 mmol, 92%).10
Protocol for 11®=W12: acid 5 (3 g, 8.89 mmol) and Wang resin (1.73 g, 2.22 mmol, 1.28
mmol/g) were coupled using DIC (1.12 g, 8.89 mmol) and DMAP (0.11 g, 0.89 mmol) following
the same procedure as above. The resultant resin 6 (PG=Fmoc) was treated with 20%
piperidine at ambient temperature for 1 h, washed with DMF and DCM, and dried to give
Wang-derived resin 9®=W. Reductive amination following the same procedure as for making
Merrifield-derived resin 10®=M afforded Wang-derived resin 10®=W. This resin was treated with
phenyl isocyanate (1 g, 8.89 mmol) in THF (10 mL) at rt for 10 h, washed with DMF, THF,
and DCM, and dried to afford the urea bound Wang-derived resin 11®=W. Treatment of this
resin with Et3N (0.9 g, 8.89 mmol) in THF (20 mL) at 60°C overnight, washes of the resin with
THF, and concentration of the combined filtrate afforded hydantoin 12 (0.638 g, 2.28 mmol,
94%) as a liquid.
These reactivity differences dictate the selection of Wang resin for library production targeting
N1-substituted hydantoins since Merrifield-derived resin suffers premature cyclo-elimination of
the final hydantoin product during filtration and resin washing. Merrifield resin can be
effectively employed in the production of N1-unsubstituted hydantoins.
Acknowledgements
We are grateful to the National Science Foundation for financial support of this research. The
400 MHz and 300 MHz NMR spectrometers used in this study were funded in part by a grant
from NSF (CHE-9808183).
References
1. Fields, G. B.; Tian, Z.; Barany, G. Principles and practice of solid-phase peptide synthesis. In Synthetic Peptides:
A User’s Guide; Grant, G. A., Ed. W. H. Freeman: New York, 1992; pp. 77–183.
2. (a) Park, K.-H.; Kurth, M. J. Drugs Fut. 2000, in press. (b) See Refs. 3, 4, and 5.
3. DeWitt, S. H.; Kieley, J. S.; Stankovic, C. J.; Schroeder, M. C.; Cody, D. M. R.; Pavia, M. R. Proc. Natl. Acad.
Sci. USA 1993, 90, 6909.
4. (a) See reference 3. (b) Kim, S. W.; Ahn, S. Y.; Koh, J. S.; Lee, J. H.; Ro, S.; Cho, H. Y. Tetrahedron Lett. 1997,
38, 4603. (c) Mattews, J.; Rivero, R. A. J. Org. Chem. 1997, 62, 6090. (d) Scicinski, J. J.; Barker, M. D.; Murray,
P. J.; Jarvie, E. M. Bioorg. Med. Chem. Lett. 1998, 8, 3609.
5. (a) Hanessian, S.; Yang, R. Y. Tetrahedron Lett. 1996, 37, 5835. (b) Dressman, B. A.; Spangle, L. A.; Kaldor,
S. W. Tetrahedron Lett. 1996, 37, 937. (c) Park, K.-H.; Olmstead, M. M.; Kurth, M. J. J. Org. Chem. 1998, 63,
6579. (d) Park, K.-H.; Abbate, E.; Najdi, S.; Olmstead, M. M.; Kurth, M. J. Chem. Commun. 1998, 1679.
6. See reference 5d.
1
7. 8: FTIR (KBr) 1778, 1702 cm−1; H NMR (300 MHz, CDCl3) l 7.44–7.35 (m, 5H), 6.96 (s, 1H), 5.81–5.72 (m,
1H), 5.25–5.19 (m, 2H), 4.18 (t, 2H, J=5.5 Hz), 2.71–2.65 (m, 2H), 2.56–2.48 (m, 2H). 13C NMR (75 MHz,
CDCl3) l 172.3, 156.8, 131.3, 130.8, 129.0, 128.2, 126.1, 120.3, 56.4, 35.9.
8. Park, K.-H.; Kurth, M. J. Tetrahedron Lett. 1999, 40, 5841.